Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive publishing date : 2022 - 05 - 20 save search
Live Nation Moves To Paid Internship Program And Receives 15,000 Applicants For 50 College Associate Positions
Published: 2022-05-20 (Crawled : 15:20) - livenationentertainment.com
LYV | $89.96 0.36% 0.0% 2.5M
|
Consumer Services
|
| O: -0.14%
H: 2.11%
C: -1.21%
nation program positive
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy
Published: 2022-05-20 (Crawled : 15:00) - biospace.com/
CLPT | $5.35 -0.74% -0.75% 130K
|
Health Technology
|
| O: 3.37%
H: 14.61%
C: 9.89%
chmp therapeutics positive therapy
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency
Published: 2022-05-20 (Crawled : 14:00) - globenewswire.com
CLPT | $5.35 -0.74% -0.75% 130K
|
Health Technology
|
| O: 3.37%
H: 14.61%
C: 9.89%
chmp therapeutics positive therapy
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Published: 2022-05-20 (Crawled : 13:00) - prnewswire.com
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 3.14%
H: 1.88%
C: -1.88%
treatment chmp zokinvy positive
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
Published: 2022-05-20 (Crawled : 13:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: 6.65%
H: 0.0%
C: 0.0%
nexpovio treatment chmp positive group
PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
Published: 2022-05-20 (Crawled : 12:20) - prnewswire.com
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 1.96%
H: 1.95%
C: -1.52%
treatment chmp therapeutics positive
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 3.42%
H: 2.83%
C: 2.7%
ptr-01 treatment pharma trial positive therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.